Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction

MEK1/2 inhibitors are clinically approved for the treatment of BRAF-mutant melanoma, where they are used in combination with BRAF inhibitors, and are undergoing evaluation in other malignancies. Acquired resistance to MEK1/2 inhibitors, including selumetinib (AZD6244/ARRY-142866), can arise through...

Descripción completa

Detalles Bibliográficos
Autores principales: Sale, Matthew J., Balmanno, Kathryn, Cook, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992624/
https://www.ncbi.nlm.nih.gov/pubmed/35582726
http://dx.doi.org/10.20517/cdr.2019.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992624/
https://www.ncbi.nlm.nih.gov/pubmed/35582726
http://dx.doi.org/10.20517/cdr.2019.14

Ejemplares similares